Acarix AB (publ) (ACARIX) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Acarix Ab.

Watch the replay

Replay transcript excerpt

WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a04003-244f-7ba0-b4f8-cb271f02b0ad Created: 2026-08-26T21:39:04.235Z Duration: 969.504 Channels: 1 00:00:00.000 -- 00:00:02.159 Good morning, and welcome to the q two 00:00:02.159 -- 00:00:05.040 twenty twenty six Acarix earnings call. I appreciate 00:00:05.040 -- 00:00:06.160 everybody joining. 00:00:08.240 -- 00:00:10.719 For our new investors and for those who 00:00:10.719 -- 00:00:12.000 who have been with us a while, I 00:00:12.000 -- 00:00:13.519 always like to start out with a little 00:00:13.519 -- 00:00:14.799 bit of an assessment as to who we 00:00:14.799 -- 00:00:17.105 are and what we do. The Casper system 00:00:17.105 -- 00:00:19.825 produced by Acarix is a highly high fidelity 00:00:19.825 -- 00:00:22.064 acoustic device that has the ability to listen 00:00:22.064 -- 00:00:23.824 into the coronary arteries 00:00:23.904 -- 00:00:25.664 of a patient's heart at point of care. 00:00:25.985 -- 00:00:27.585 And what we're able to derive 00:00:27.825 -- 00:00:30.599 from our negative predictive value of 96.2 00:00:30.599 -- 00:00:32.920 is very high productivity in regards to being 00:00:32.920 -- 00:00:35.320 able to rule out coronary artery disease at 00:00:35.320 -- 00:00:37.000 point of care just in a few minutes, 00:00:37.000 -- 00:00:39.000 four to six minutes on average. 00:00:39.239 -- 00:00:41.239 We have over fifteen years of r and 00:00:41.239 -- 00:00:44.840 d, over 45 patents, and well over 60,000 00:00:44.415 -- 00:00:46.655 assessments worldwide, 00:00:46.975 -- 00:00:49.775 along with 6,000 patients in clinical trials continually 00:00:49.775 -- 00:00:51.455 building our robust outcomes. 00:00:51.855 -- 00:00:54.495 From a from a regulatory standpoint, we are 00:00:54.495 -- 00:00:56....